Drug
D-methadone clinical trials
Also written REL-1017 and esmethadone.
A product of Methadone; its studies count on that page too.
- studies test it
- 11
- open now
- 0
- in phase 3
- 6
- first study started
- 2004
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2018 | 1 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 3
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 2
Relmada Therapeutics, Inc. (6) · Levomecor Inc. (2) · Memorial Sloan Kettering Cancer Center (1) · Mauro Manconi (1) · MGGM LLC (1)
Studies
Open first, then newest update. How each study uses D-methadone is read from its arms, and is right about nine times in ten.
Testing it · 11
- A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)TerminatedPhase 3Levomecor Inc.NCT04855747Written as REL-1017
- Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDDTerminatedPhase 3Levomecor Inc.NCT06011577Written as REL-1017
- A Proof of Concept, Phase 2, Double-blind, Randomized Trial With d-Methadone Product Versus PlaceboSuspendedPhase 2Mauro ManconiNCT04145674Written as D-methadone
- Safety of REL-1017 for Major Depressive DisorderCompletedPhase 3Relmada Therapeutics, Inc.NCT04855760Written as REL-1017
- A Study to Evaluate the Efficacy and Safety of REL-1017 As Adjunctive Treatment of Major Depressive Disorder (MDD)WithdrawnPhase 3MGGM LLCNCT06735079Written as REL1017 (esmethadone HCI) (active drug)
- A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)CompletedPhase 3Relmada Therapeutics, Inc.NCT04688164Written as REL-1017
- A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)CompletedPhase 3Relmada Therapeutics, Inc.NCT05081167Written as REL-1017
- Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDDCompletedPhase 2Relmada Therapeutics, Inc.NCT03051256Written as REL-1017
- Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of REL-1017 (d-Methadone)CompletedPhase 1Relmada Therapeutics, Inc.NCT03637361Written as REL-1017
- Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REL-1017 (d-Methadone)CompletedPhase 1Relmada Therapeutics, Inc.NCT03638869Written as REL-1017
- Study of D-Methadone in Patients With Chronic PainCompletedPhase 1/2Memorial Sloan Kettering Cancer CenterNCT00588640Written as d-Methadone
Codes
What other systems call D-methadone · ClinicalTrials.gg INT000918
- MeSH (NLM) C000626862D-methadoneOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000626862 | D-methadone | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.